DOCSLIB.ORG

Drug Consumption in Current Year (Period 201901

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Page 1 Drug consumption in current year (Period 202001 - 202012) Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change % A ALIMENTARY TRACT AND METABOLISM 323,80 3 4 321 589 7 4 A01 STOMATOLOGICAL PREPARATIONS 14,28 4 12 2 090 9 8 A01A STOMATOLOGICAL PREPARATIONS 14,28 4 12 2 090 9 8 A01AA Caries prophylactic agents 11,90 3 14 663 8 9 A01AA01 sodium fluoride 11,90 3 14 610 8 10 A01AA03 olaflur - - - 53 1 -2 A01AB Antiinfectives for local oral treatment 2,36 8 2 1 266 10 15 A01AB03 chlorhexidine 2,02 6 -3 930 6 5 A01AB11 various 0,33 21 57 335 21 55 A01AB22 doxycycline - - - 0 - -100 A01AC Corticosteroids for local oral treatment - - - 113 1 -26 A01AC01 triamcinolone - - - 113 1 -26 A01AD Other agents for local oral treatment 0,02 0 -28 49 0 -32 A01AD02 benzydamine 0,02 0 -28 49 0 -32 A02 DRUGS FOR ACID RELATED DISORDERS 73,05 3 3 30 885 4 -5 A02A ANTACIDS 2,23 1 1 3 681 1 3 A02AA Magnesium compounds 0,07 22 -7 141 22 -7 A02AA04 magnesium hydroxide 0,07 22 -7 141 22 -7 A02AD Combinations and complexes of aluminium, 2,17 0 1 3 539 0 4 calcium and magnesium compounds A02AD01 ordinary salt combinations 2,17 0 1 3 539 0 4 A02B DRUGS FOR PEPTIC ULCER AND 70,82 3 3 27 205 5 -7 GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 0,17 7 -77 551 10 -29 A02BA02 ranitidine 0,00 1 -100 1 1 -100 A02BA03 famotidine 0,16 7 48 550 10 43 A02BB Prostaglandins 0,04 62 55 80 62 55 A02BB01 misoprostol 0,04 62 55 80 62 55 A02BC Proton pump inhibitors 69,26 3 4 23 531 4 -8 A02BC01 omeprazole 8,62 2 -2 2 406 3 -5 A02BC02 pantoprazole 37,89 4 6 8 047 8 -15 A02BC03 lansoprazole 5,47 1 -3 1 205 1 -42 Page 2 Drug consumption in current year (Period 202001 - 202012) Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change % A02BC04 rabeprazole 1,59 1 8 922 1 8 A02BC05 esomeprazole 15,68 2 5 10 950 3 3 A02BD Combinations for eradication of Helicobacter pylori 0,02 0 -35 218 0 -28 A02BD03 lansoprazole, metronidazole and amoxicillin 0,00 0 -69 23 0 -69 A02BD07 lansoprazole, amoxicillin and clarithromycin 0,02 0 -14 196 0 -14 A02BX Other drugs for peptic ulcer and 1,33 8 11 2 825 7 17 gastro-oesophageal reflux disease (GORD) A02BX02 sucralfate 0,35 22 20 574 21 21 A02BX13 alginic acid 0,98 3 7 2 251 3 16 A03 DRUGS FOR FUNCTIONAL 2,67 10 -2 5 455 46 -7 GASTROINTESTINAL DISORDERS A03A DRUGS FOR FUNCTIONAL 1,17 7 -5 1 895 19 1 GASTROINTESTINAL DISORDERS A03AB Synthetic anticholinergics, quaternary ammonium 0,05 87 -3 372 87 -3 compounds A03AB02 glycopyrronium bromide 0,05 87 -3 372 87 -3 A03AX Other drugs for functional gastrointestinal disorders 1,12 3 -5 1 523 2 2 A03AX13 silicones 1,12 3 -5 1 389 3 -6 A03AX15 menthae piperitae aetheroleum - - - 135 0 640 A03B BELLADONNA AND DERIVATIVES, PLAIN 0,04 93 -34 344 93 -47 A03BA Belladonna alkaloids, tertiary amines 0,04 93 -36 285 92 -49 A03BA01 atropine 0,04 93 -36 285 92 -49 A03BB Belladonna alkaloids semisynthetic, quaternary 0,00 97 0 59 96 -32 ammonium compounds A03BB01 butylscopolamine 0,00 97 0 59 96 -32 A03C ANTISPASMODICS IN COMBINATION WITH 0,18 1 -11 196 1 -12 PSYCHOLEPTICS A03CA Synthetic anticholinergic agents in combination 0,18 1 -11 196 1 -12 with psycholeptics A03CA02 clidinium and psycholeptics 0,18 1 -11 196 1 -12 A03D ANTISPASMODICS IN COMBINATION WITH 0,26 11 13 2 599 64 -4 ANALGESICS A03DA Synthetic anticholinergic agents in combination 0,26 11 13 2 599 64 -4 with analgesics Page 3 Drug consumption in current year (Period 202001 - 202012) Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change % A03DA02 pitofenone and analgesics 0,26 11 13 2 599 64 -4 A03F PROPULSIVES 1,01 11 1 421 35 9 A03FA Propulsives 1,01 11 1 421 35 9 A03FA01 metoclopramide 1,01 11 1 421 35 9 A04 ANTIEMETICS AND ANTINAUSEANTS 0,30 43 2 4 860 48 16 A04A ANTIEMETICS AND ANTINAUSEANTS 0,30 43 2 4 860 48 16 A04AA Serotonin (5HT3) antagonists 0,24 47 2 4 128 48 23 A04AA01 ondansetron 0,16 47 6 1 864 65 86 A04AA02 granisetron 0,06 43 -4 851 41 -2 A04AA05 palonosetron 0,01 100 -16 257 99 -13 A04AA55 palonosetron, combinations 0,01 15 7 1 157 15 -2 A04AD Other antiemetics 0,06 28 2 731 49 -14 A04AD01 scopolamine 0,06 26 5 373 26 24 A04AD12 aprepitant 0,01 50 -13 359 73 -32 A04AD14 rolapitant - - -100 0 - -100 A05 BILE AND LIVER THERAPY 0,92 3 -2 1 414 3 -37 A05A BILE THERAPY 0,92 3 -2 1 414 3 -37 A05AA Bile acids and derivatives 0,92 3 -2 1 414 3 -37 A05AA02 ursodeoxycholic acid 0,92 3 -2 1 342 3 -39 A05AA04 obeticholic acid 0,00 4 108 72 4 108 A06 DRUGS FOR CONSTIPATION 51,34 8 7 29 145 11 7 A06A DRUGS FOR CONSTIPATION 51,34 8 7 29 145 11 7 A06AB Contact laxatives 6,31 5 2 3 740 7 -1 A06AB02 bisacodyl 0,71 2 -22 265 2 -27 A06AB06 senna glycosides 0,13 0 -14 52 0 -13 A06AB08 sodium picosulfate 5,48 6 7 2 819 4 5 A06AB56 senna glycosides, combinations - - - 163 0 -3 A06AB58 sodium picosulfate, combinations 0,00 30 -12 441 31 -13 A06AC Bulk-forming laxatives 12,01 1 12 5 859 2 11 A06AC01 ispaghula (psylla seeds) 11,43 1 13 5 629 2 11 A06AC51 ispaghula, combinations 0,59 1 -3 230 1 -3 A06AD Osmotically acting laxatives 31,51 11 7 16 138 12 9 A06AD11 lactulose 13,23 9 -1 2 630 9 -3 A06AD15 macrogol 17,20 13 16 11 751 12 15 Page 4 Drug consumption in current year (Period 202001 - 202012) Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change % A06AD17 sodium phosphate - - - 41 18 -25 A06AD65 macrogol, combinations 1,08 3 -13 1 716 21 -3 A06AG Enemas 1,31 10 -4 2 419 17 -4 A06AG02 bisacodyl 0,24 33 -2 414 32 -2 A06AG10 docusate sodium, incl. combinations 0,06 49 -7 555 45 -6 A06AG11 laurilsulfate, incl. combinations 1,01 3 -4 1 450 2 -4 A06AH Peripheral opioid receptor antagonists 0,13 28 22 756 39 21 A06AH01 methylnaltrexone bromide 0,00 97 12 133 97 12 A06AH03 naloxegol 0,13 26 22 624 26 24 A06AX Other drugs for constipation 0,06 9 36 233 11 29 A06AX04 linaclotide 0,03 1 71 111 1 69 A06AX05 prucalopride 0,02 20 7 122 20 7 A07 ANTIDIARRHEALS, INTESTINAL 14,08 2 0 29 004 5 -2 ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS A07A INTESTINAL ANTIINFECTIVES 0,17 21 21 2 666 34 11 A07AA Antibiotics 0,17 21 21 2 666 34 11 A07AA02 nystatin 0,07 18 6 679 18 2 A07AA09 vancomycin 0,01 53 0 687 53 -2 A07AA11 rifaximin 0,09 20 40 1 026 20 40 A07AA12 fidaxomicin 0,00 73 -6 274 73 -6 A07B INTESTINAL ADSORBENTS 0,14 55 9 668 54 -1 A07BA Charcoal preparations 0,14 55 9 668 54 -1 A07BA01 medicinal charcoal 0,14 55 9 668 54 -1 A07C ELECTROLYTES WITH CARBOHYDRATES 0,01 5 -40 138 5 -40 A07CA Oral rehydration salt formulations 0,01 5 -40 138 5 -40 A07D ANTIPROPULSIVES 1,20 2 -12 3 788 1 -14 A07DA Antipropulsives 1,20 2 -12 3 788 1 -14 A07DA03 loperamide 1,20 2 -12 2 962 1 -13 A07DA06 eluxadoline - - -100 0 - -100 A07DA53 loperamide, combinations - - - 825 0 -19 A07E INTESTINAL ANTIINFLAMMATORY AGENTS 11,75 1 5 18 973 1 6 A07EA Corticosteroids acting locally 0,85 3 7 1 976 3 8 A07EA06 budesonide 0,85 3 7 1 976 3 8 A07EC Aminosalicylic acid and similar agents 10,90 1 5 16 997 1 5 Page 5 Drug consumption in current year (Period 202001 - 202012) Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change % A07EC01 sulfasalazine 3,26 1 2 2 937 1 2 A07EC02 mesalazine 7,63 1 6 14 046 1 6 A07EC03 olsalazine 0,01 3 -31 14 3 -31 A07F ANTIDIARRHEAL MICROORGANISMS 0,82 4 -31 2 473 4 -31 A07FA Antidiarrheal microorganisms 0,82 4 -31 2 473 4 -31 A07FA01 lactic acid producing organisms - - -100 0 - -100 A07FA02 saccharomyces boulardii 0,82 4 -31 2 473 4 -31 A07X OTHER ANTIDIARRHEALS - - - 299 7 -34 A07XA Other antidiarrheals - - - 299 7 -34 A07XA04 racecadotril - - - 299 7 -34 A08 ANTIOBESITY PREPARATIONS, EXCL. DIET 0,07 0 -15 602 0 -6 PRODUCTS A08A ANTIOBESITY PREPARATIONS, EXCL. DIET 0,07 0 -15 602 0 -6 PRODUCTS A08AA Centrally acting antiobesity products - - - 334 0 -6 A08AA62 bupropion and naltrexone - - - 334 0 -6 A08AB Peripherally acting antiobesity products 0,07 0 -15 268 0 -5 A08AB01 orlistat 0,07 0 -15 268 0 -5 A09 DIGESTIVES, INCL. ENZYMES 1,86 4 0 3 146 4 -2 A09A DIGESTIVES, INCL.
Recommended publications
  • WO 2017/048702 Al

    WO 2017/048702 Al

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2017/048702 A l 2 3 March 2017 (23.03.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 487/04 (2006.01) A61P 35/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/519 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 16/05 1490 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 13 September 2016 (13.09.201 6) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/218,493 14 September 2015 (14.09.2015) US (84) Designated States (unless otherwise indicated, for every 62/218,486 14 September 2015 (14.09.2015) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: INFINITY PHARMACEUTICALS, INC.
  • New Insights Into the Effect of Amorolfine Nail Lacquer

    New Insights Into the Effect of Amorolfine Nail Lacquer

    Review article New insights into the effect of amorolfine nail lacquer C. Flagothier, C. Pie´ rard-Franchimont and G. E. Pie´ rard Department of Dermatopathology, University Hospital of Lie`ge, Lie`ge, Belgium Summary Despite improvements in antifungal strategies, the outcome of treating onychomycoses often remains uncertain. Several factors account for treatment failure, of which the pharmacokinetics and pharmacodynamics of the antifungal are of importance. The taxonomic nature and ungual location of the fungus cannot be neglected, besides the type of nail and its growth rate. In addition, the biological cycle of the fungus and the metabolic activity of the pathogen likely play a marked influence in drug response. The presence of natural antimicrobial peptides in the nail is also probably a key feature controlling the cure rates. There are many outstanding publications that cover the full spectrum of the field. The purpose of this review is to put in perspective some facets of activity of the topical treatment using amorolfine nail laquer. The antifungal activity of the drug is likely less pronounced in onychomycosis than that expected from conventional in vitro studies. However, the nail laquer formulation should reduce the propensity to form antifungal-resistant spores and limit the risk of reinfection. Key words: amorolfine, antifungal, fungus, onychomycosis, spore. Topical treatments are often considered to be less Introduction efficacious than current oral treatments. However, some During the last 2 decades, the efficacy of treating topical formulations may provide effects that cannot be onychomycoses has been considerably improved by achieved by other treatments. In discussing the treat- the introduction of new generations of potent antifun- ment of onychomycosis, it should not be forgotten that gals.
  • The Impact of a Changed Legislation on Reporting of Adverse Drug Reactions in Sweden, with Focus on Nurses Reporting

    The Impact of a Changed Legislation on Reporting of Adverse Drug Reactions in Sweden, with Focus on Nurses Reporting

    The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses reporting Sofia A. Karlsson, Ingela Jacobsson, Marit Danell Boman, Katja M. Hakkarainen, Henrik Lövborg, Staffan Hägg and Anna K Jönsson Linköping University Post Print N.B.: When citing this work, cite the original article. The original publication is available at www.springerlink.com: Sofia A. Karlsson, Ingela Jacobsson, Marit Danell Boman, Katja M. Hakkarainen, Henrik Lövborg, Staffan Hägg and Anna K Jönsson, The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses reporting, 2015, European Journal of Clinical Pharmacology, (71), 5, 631-636. http://dx.doi.org/10.1007/s00228-015-1839-6 Copyright: Springer Verlag (Germany) http://www.springerlink.com/?MUD=MP Postprint available at: Linköping University Electronic Press http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-118037 The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses’ reporting Sofia A Karlsson1, Ingela Jacobsson2, Marit Danell Boman3, Katja M Hakkarainen4,5, Henrik Lövborg2, Staffan Hägg2,5, Anna K Jönsson2 Affiliations: 1. Department of Public Health and Community Medicine, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden 2. Department of Clinical Pharmacology and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden 3. Division of Clinical Pharmacology, University Hospital of Umeå, Umeå, Sweden 4. Nordic School of
  • The Management of Common Skin Conditions in General Practice

    The Management of Common Skin Conditions in General Practice

    Management of Common Skin Conditions In General Practice including the “red rash made easy” © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care University of Auckland, Tamaki Campus Reviewed by Hon A/Prof Amanda Oakley - 2019 http://www.dermnetnz.org Management of Common Skin Conditions In General Practice Contents Page Derm Map 3 Classic location: infants & children 4 Classic location: adults 5 Dermatology terminology 6 Common red rashes 7 Other common skin conditions 12 Common viral infections 14 Common bacterial infections 16 Common fungal infections 17 Arthropods 19 Eczema/dermatitis 20 Benign skin lesions 23 Skin cancers 26 Emergency dermatology 28 Clinical diagnosis of melanoma 31 Principles of diagnosis and treatment 32 Principles of treatment of eczema 33 Treatment sequence for psoriasis 34 Topical corticosteroids 35 Combination topical steroid + antimicrobial 36 Safety with topical corticosteroids 36 Emollients 37 Antipruritics 38 For further information, refer to: http://www.dermnetnz.org And http://www.derm-master.com 2 © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care, University of Auckland, Tamaki Campus. Management of Common Skin Conditions In General Practice DERM MAP Start Is the patient sick ? Yes Rash could be an infection or a drug eruption? No Insect Bites – Crop of grouped papules with a central blister or scab. Is the patient in pain or the rash Yes Infection: cellulitis / erysipelas, impetigo, boil is swelling, oozing or crusting? / folliculitis, herpes simplex / zoster. Urticaria – Smooth skin surface with weals that evolve in minutes to hours. No Is the rash in a classic location? Yes See our classic location chart .
  • Assessing the Availability, Service Quality, and Price of Essential Medicines In

    Assessing the Availability, Service Quality, and Price of Essential Medicines In

    Assessing the Availability, Service Quality, and Price of Essential Medicines in Private Pharmacies in Afghanistan Norio Kasahara A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2015 Reading Committee: Louis P. Garrison, Jr., Chair Joseph B. Babigumira Andy Stergachis Program Authorized to Offer Degree: Pharmaceutical Outcomes Research and Policy ©Copyright 2015 Norio Kasahara ii Table of Contents Abstract ................................................................................................................................................................................... ................................................................................................ ................................................................................................ .................................................................................. ............... vvv Acknowledgements ................................................................................................................................................................................... ................................................................................................ ................................................................................. ............ viiviivii Summary ................................................................................................................................................................................... ...............................................................................................
  • Summary of Product Characteristics

    Summary of Product Characteristics

    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Salbutamol CFC-Free Inhaler 100 micrograms per metered dose, pressurised inhalation, suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One metered dose contains 100 micrograms of salbutamol (equivalent to 120 micrograms of salbutamol sulphate). This is equivalent to a delivered dose of 90 micrograms of salbutamol (equivalent to 108 micrograms of salbutamol sulphate). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Pressurised inhalation suspension Pressurised inhalation suspension supplied in an aluminium canister with a metering valve and a plastic actuator and dust cap. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Salbutamol CFC-Free Inhaler is indicated in adults, adolescents and children. For babies and children under 4 years of age, see sections 4.2 and 5.1. Salbutamol CFC-Free Inhaler is indicated for the relief and prevention of bronchial asthma and conditions associated with reversible airways obstruction. Salbutamol CFC-Free Inhaler can be used as relief medication in the management of mild, moderate or severe asthma, provided that its use does not delay the introduction and use of regular inhaled corticosteroid therapy, where necessary. 4.2 Posology and method of administration Salbutamol CFC-Free Inhaler is for oral inhalation use only. Posology Adults (including the elderly) and adolescents (children 12 years and over): For the relief of acute bronchospasm, one inhalation (100 micrograms) increasing to two inhalations (200 micrograms), if necessary. To prevent allergen- or exercise-induced symptoms, two inhalations (200 micrograms) should be taken 10-15 minutes before challenge. Maximum daily dose: two inhalations (200 micrograms) up to four times a day.
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play

    Health Reports for Mutual Recognition of Medical Prescriptions: State of Play

    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
  • Teriparatide Injection I.P. (R-DNA Origin) Interactions Were Noted

    Teriparatide Injection I.P. (R-DNA Origin) Interactions Were Noted

    PA011FSRI04 For more information, visit us at www.lillyindia.co.in Interactions with other medicinal products and other forms of interaction Forteo® has been evaluated in pharmacodynamic interaction studies with hydrochlorothiazide. No clinically significant Teriparatide Injection I.P. (r-DNA origin) interactions were noted. ® Co-administration of raloxifene or hormone replacement therapy with Forteo® did not alter the effects of Forteo® on Forteo serum or urine calcium or on clinical adverse events. (600mcg/2.4mL, Solution for injection in a pre-filled pen) In a study of 15 healthy subjects administered digoxin daily to steady state, a single Forteo® dose did not alter the cardiac effect of digoxin. However, sporadic case reports have suggested that hypercalcaemia may predispose patients to digitalis toxicity. Because Forteo® transiently increases serum calcium, Forteo® should be used with caution in patients taking digitalis NAME OF THE MEDICINAL PRODUCT Fertility, pregnancy and lactation Fertility Forteo® 600mcg/2.4mL, solution for injection, in pre-filled pen. Studies in rabbits have shown reproductive toxicity (see section Preclinical safety data). The effect of teriparatide on human foetal development has not been studied. The potential risk for humans is unknown. QUALITATIVE AND QUANTITATIVE COMPOSITION Pregnancy Each mL of Teriparatide Injection I.P. contains: 250 mcg Teriparatide I.P. (r-DNA origin) as active ingredient, Forteo® is contraindicated for use during pregnancy (see section Contraindications) 0.41 mg Glacial Acetic Acid I.P. as buffering agent, 0.10 mg Sodium Acetate (Anhydrous) I.P. as buffering agent, Breast –Feeding 45.4 mg Mannitol I.P. as tonicity modifier, 3.0 mg Metacresol Ph.
  • Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020

    Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020

    First independent framework for assessing pharmaceutical company action Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020 ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report.1 FUNDERS The Antimicrobial Resistance Benchmark research programme is made possible with financial support from UK AID and the Dutch Ministry of Health, Welfare and Sport. Expert Review Committee Research Team Reviewers Hans Hogerzeil - Chair Gabrielle Breugelmans Christine Årdal Gregory Frank Fatema Rafiqi Karen Gallant Nina Grundmann Adrián Alonso Ruiz Hans Hogerzeil Magdalena Kettis Ruth Baron Hitesh Hurkchand Joakim Larsson Dulce Calçada Joakim Larsson Marc Mendelson Moska Hellamand Marc Mendelson Margareth Ndomondo-Sigonda Kevin Outterson Katarina Nedog Sarah Paulin (Observer) Editorial Team Andrew Singer Anna Massey Deirdre Cogan ACCESS TO MEDICINE FOUNDATION Rachel Jones The Access to Medicine Foundation is an independent Emma Ross non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income Additional contributors countries by stimulating and guiding the pharmaceutical Thomas Collin-Lefebvre industry to play a greater role in improving access to Alex Kong medicine. Nestor Papanikolaou Address Contact Naritaweg 227-A For more information about this publication, please contact 1043 CB, Amsterdam Jayasree K. Iyer, Executive Director The Netherlands [email protected] +31 (0) 20 215 35 35 www.amrbenchmark.org 1 This acknowledgement is not intended to imply that the individuals and institutions referred to above endorse About the cover: Young woman from the Antimicrobial Resistance Benchmark methodology, Brazil, where 40%-60% of infections are analyses or results.
  • Penile Injection Therapy | Memorial Sloan Kettering Cancer Center

    Penile Injection Therapy | Memorial Sloan Kettering Cancer Center

    PATIENT & CAREGIVER EDUCATION Penile Injection Therapy This information will help you learn to inject medication into your penis. This is called penile injection therapy. Penile injections can help you achieve an erection if you have erectile dysfunction (ED). Read this resource carefully before starting injection therapy. If you do not follow the instructions in this resource, your doctor or APP may stop prescribing your penile injection medications and supplies. About Penile Injection Therapy The tissue that causes you to get an erection (erectile tissue) is a muscle. Going long periods of time without an erection is unhealthy for erectile tissue and may damage it. We believe having erections keeps erectile tissue healthy. A penile injection helps you have an erection. It works best if it’s given about 5 to 15 minutes before you want an erection. Penile Injection Therapy 1/19 Giving Yourself the Injection Your advanced practice provider (APP) will review the instructions below with you. Generally, the training for the injections takes 2 office visits. Please be aware that each visit may take up to 1 hour, so you should plan your schedule on the day of your appointment. Use this resource to help you the first few times you inject on your own. Do not take the following medications within 18 hours of injecting (before or after): Sildenafil (Viagra®) - 20 mg to 100 mg Vardenafil (Levitra®) - 10 mg to 20 mg Avanafil (Stendra®) - 50 mg to 200 mg If you take tadalafil (Cialis®) 10 mg or 20 mg, do not inject within 72 hours (3 days) of taking the medication.
  • Oral Anticoagulants

    Oral Anticoagulants

    4/26/2018 Disclosure • Kelsey Gander, PharmD, BCACP Direct Oral Anticoagulants: – Declares no financial relationships pertinent to this session When to Use and How to Choose – Declares off-label use of medication will not be discussed during this presentation. Kelsey Gander, PharmD, BCACP Minnesota Academy of Physician Assistants Conference May 11th, 2018 Abbreviations Objectives • DOAC= direct oral anticoagulant 1) Compare and contrast the efficacy and safety • VTE= venous thromboembolism • DVT= deep vein thrombosis of direct oral anticoagulants (DOACs) to • PE= pulmonary embolism warfarin • A-fib, AF= atrial fibrillation 2) Identify which anticoagulant would be most • ESRD= end stage renal disease appropriate for a given patient • ACC= American College of Cardiology • AHA= American Heart Association 3) Recognize when it would not be appropriate • HRS= Heart Rhythm Society to use a DOAC • BID= twice daily Appropriate Abbreviations Patient Case JJ is a 66 y/o male who was hospitalized for pulmonary • NOAC embolism and initiated on anticoagulant therapy one week – Novel Oral Anticoagulant ago. – Chief complaint: – Non-Vitamin K Oral Anticoagulant • Presents to clinic today for INR check, post-hospital discharge follow- up • TSOAC – Past medical history: • Hypertension, hyperlipidemia, osteoarthritis, erectile dysfunction, – Target Specific Oral Anticoagulant BPH, type 2 diabetes, peripheral artery disease – Home medications • DOAC • Acetaminophen 650mg po every 6 hours PRN – Direct Oral Anticoagulant • Diazepam 5mg po at bedtime PRN anxiety
  • Orphan Drugs Used for Treatment in Pediatric Patients in the Slovak Republic

    Orphan Drugs Used for Treatment in Pediatric Patients in the Slovak Republic

    DOI 10.2478/v10219-012-0001-0 ACTA FACULTATIS PHARMACEUTICAE UNIVERSITATIS COMENIANAE Supplementum VI 2012 ORPHAN DRUGS USED FOR TREATMENT IN PEDIATRIC PATIENTS IN THE SLOVAK REPUBLIC 1Foltánová, T. – 2Konečný, M. – 3Hlavatá, A. –.4Štepánková, K. 5Cisárik, F. 1Comenius University in Bratislava, Faculty of Pharmacy, Department of Pharmacology and Toxicology 2Department of Clinical Genetics, St. Elizabeth Cancer Institute, Bratislava 32nd Department of Pediatrics, UniversityChildren'sHospital, Bratislava 4Slovak Cystic Fibrosis Association, Košice 5Department of Medical Genetics, Faculty Hospital, Žilina Due to the enormous success of scientific research in the field of paediatric medicine many once fatal children’s diseases can now be cured. Great progress has also been achieved in the rehabilitation of disabilities. However, there is still a big group of diseases defined as rare, treatment of which has been traditionally neglected by the drug companies mainly due to unprofitability. Since 2000 the treatment of rare diseases has been supported at the European level and in 2007 paediatric legislation was introduced. Both decisions together support treatment of rare diseases in children. In this paper, we shortly characterise the possibilities of rare diseases treatment in children in the Slovak republic and bring the list of orphan medicine products (OMPs) with defined dosing in paediatrics, which were launched in the Slovak market. We also bring a list of OMPs with defined dosing in children, which are not available in the national market. This incentive may help in further formation of the national plan for treating rare diseases as well as improvement in treatment options and availability of rare disease treatment in children in Slovakia.